Human amniotic epithelial cell therapy- Shanghai iCELL Biotechnology/The Second Affiliated Hospital of Chongqing Medical University

Drug Profile

Human amniotic epithelial cell therapy- Shanghai iCELL Biotechnology/The Second Affiliated Hospital of Chongqing Medical University

Alternative Names: hAECs

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai iCELL Biotechnology
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Genitourinary disorders

Most Recent Events

  • 27 Jul 2017 The Second Affiliated Hospital of Chongqing Medical University in collaboration with Shanghai iCELL Biotechnology plans a phase I trial for Genitourinary disorders (Asherman's syndrome) (Second-line therapy) in October 2017 (NCT03223454)
  • 13 Jul 2017 Preclinical trials in Genitourinary disorders in China (Intrauterine) before July 2017 (NCT03223454)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top